ETHACRYNIC ACID

Post-LOE

Alvogen

ANDAORALTABLET

Approved

Jul 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ETHACRYNIC ACID by Alvogen is clinical pharmacology pharmacokinetics and metabolism ethacrynic acid acts on the ascending limb of the loop of henle and on the proximal and distal tubules. Approved for edema. First approved in 2018.

Drug data last refreshed Yesterday

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased…

Indications (1)

Worked on ETHACRYNIC ACID at Alvogen? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.